SVB MoffettNathanson Upgrades Reata Pharmaceuticals (RETA) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RETA Hot Sheet
Price: $172.36 --0%
Rating Summary:
6 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
6 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
SVB MoffettNathanson analyst Joseph P. Schwartz upgraded Reata Pharmaceuticals (NASDAQ: RETA) from Market Perform to Outperform with a price target of $115.00 (from $80.00).
For an analyst ratings summary and ratings history on Reata Pharmaceuticals click here. For more ratings news on Reata Pharmaceuticals click here.
Shares of Reata Pharmaceuticals closed at $93.80 yesterday.
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Graco Inc. (GGG) PT Lowered to $80 at DA Davidson
- RingCentral (RNG) PT Raised to $105 at FBN Securities
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
